337 related articles for article (PubMed ID: 17461888)
1. Lacosamide: a review of preclinical properties.
Beyreuther BK; Freitag J; Heers C; Krebsfänger N; Scharfenecker U; Stöhr T
CNS Drug Rev; 2007; 13(1):21-42. PubMed ID: 17461888
[TBL] [Abstract][Full Text] [Related]
2. Lacosamide, a newer antiepileptic.
Patyar S; Medhi B
Neurosciences (Riyadh); 2010 Jan; 15(1):3-6. PubMed ID: 20677583
[TBL] [Abstract][Full Text] [Related]
3. Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2).
Wolff C; Carrington B; Varrin-Doyer M; Vandendriessche A; Van der Perren C; Famelart M; Gillard M; Foerch P; Rogemond V; Honnorat J; Lawson A; Miller K
CNS Neurosci Ther; 2012 Jun; 18(6):493-500. PubMed ID: 22672303
[TBL] [Abstract][Full Text] [Related]
4. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.
Wang Y; Brittain JM; Jarecki BW; Park KD; Wilson SM; Wang B; Hale R; Meroueh SO; Cummins TR; Khanna R
J Biol Chem; 2010 Aug; 285(33):25296-307. PubMed ID: 20538611
[TBL] [Abstract][Full Text] [Related]
5. Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization.
Wilson SM; Xiong W; Wang Y; Ping X; Head JD; Brittain JM; Gagare PD; Ramachandran PV; Jin X; Khanna R
Neuroscience; 2012 May; 210():451-66. PubMed ID: 22433297
[TBL] [Abstract][Full Text] [Related]
6. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain.
Harris JA; Murphy JA
Ann Pharmacother; 2009 Nov; 43(11):1809-17. PubMed ID: 19843834
[TBL] [Abstract][Full Text] [Related]
7. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
8. (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.
Moutal A; Chew LA; Yang X; Wang Y; Yeon SK; Telemi E; Meroueh S; Park KD; Shrinivasan R; Gilbraith KB; Qu C; Xie JY; Patwardhan A; Vanderah TW; Khanna M; Porreca F; Khanna R
Pain; 2016 Jul; 157(7):1448-1463. PubMed ID: 26967696
[TBL] [Abstract][Full Text] [Related]
9. Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na
Holtkamp D; Opitz T; Niespodziany I; Wolff C; Beck H
Epilepsia; 2017 Jan; 58(1):27-41. PubMed ID: 27864845
[TBL] [Abstract][Full Text] [Related]
10. Lacosamide for the treatment of epilepsy.
de Biase S; Gigli GL; Valente M; Merlino G
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):459-68. PubMed ID: 24479852
[TBL] [Abstract][Full Text] [Related]
11. Lacosamide as adjunctive therapy in treatment-resistant epilepsy in childhood.
Gulati P; Cannell P; Ghia T; Bint L; Walsh P; Ghosh S; Nagarajan L
J Paediatr Child Health; 2015 Aug; 51(8):794-7. PubMed ID: 25683595
[TBL] [Abstract][Full Text] [Related]
12. [Lacosamide. A new antiepileptic drug as adjunctive therapy in patients with partial-onset seizures].
Saussele T
Med Monatsschr Pharm; 2008 Oct; 31(10):374-7. PubMed ID: 18972867
[TBL] [Abstract][Full Text] [Related]
13. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.
Kellinghaus C
Ther Clin Risk Manag; 2009; 5():757-66. PubMed ID: 19816574
[TBL] [Abstract][Full Text] [Related]
14. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders.
Curia G; Biagini G; Perucca E; Avoli M
CNS Drugs; 2009; 23(7):555-68. PubMed ID: 19552484
[TBL] [Abstract][Full Text] [Related]
15. Inverted-U response of lacosamide on pilocarpine-induced status epilepticus and oxidative stress in C57BL/6 mice is independent of hippocampal collapsin response mediator protein-2.
Nirwan N; Siraj F; Vohora D
Epilepsy Res; 2018 Sep; 145():93-101. PubMed ID: 29935443
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
Stephen LJ; Kelly K; Parker P; Brodie MJ
Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
[TBL] [Abstract][Full Text] [Related]
17. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures.
Ben-Menachem E
Drugs Today (Barc); 2008 Jan; 44(1):35-40. PubMed ID: 18301802
[TBL] [Abstract][Full Text] [Related]
18. Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
Park KD; Morieux P; Salomé C; Cotten SW; Reamtong O; Eyers C; Gaskell SJ; Stables JP; Liu R; Kohn H
J Med Chem; 2009 Nov; 52(21):6897-911. PubMed ID: 19795888
[TBL] [Abstract][Full Text] [Related]
19. Lacosamide: new adjunctive treatment option for partial-onset seizures.
Chung SS
Expert Opin Pharmacother; 2010 Jun; 11(9):1595-602. PubMed ID: 20482307
[TBL] [Abstract][Full Text] [Related]
20. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial.
Vossler DG; Wechsler RT; Williams P; Byrnes W; Therriault S;
Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
